Federal Circuit Holds That Claims Directed To A Specific Method Of Treatment For Specific Patients Using A Specific Compound At Specific Doses To Achieve A Specific Outcome Satisfy 35 U.S.C. §101
On March 28, 2019, the Court of Appeals for the Federal Circuit (CAFC) issued an opinion in Endo Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc., reversing a decision by the United States District Court for the District of Delaware in which the District Court had held the claims of U.S. Patent No. 8,808,737 to be … Continue reading Federal Circuit Holds That Claims Directed To A Specific Method Of Treatment For Specific Patients Using A Specific Compound At Specific Doses To Achieve A Specific Outcome Satisfy 35 U.S.C. §101
Read more »